P2RY12 and atrial fibrillation: For years, the standard triple antithrombotic therapy (TAT) containing vitamin K antagonist (VKA), P2Y12 inhibitor (mainly clopidogrel), and aspirin was recommended in patients with atrial fibrillation (AF) treated with percutaneous coronary interventions (PCI).